It has been reported that p-Akt is upregulated or remains unchanged after CTX treatment in some CTX-resistant cancer cells, and some drug treatments inhibit p-Akt to sensitize these cells to CTX (1, 21). The gene discussed is AKT1; the disease is cancer.